Compared with those in the S group, the DEGs in the berberine-treated group (BS) were enriched mainly in the following pathways: the NF–κ B signalling pathway, B cell receptor signalling pathway, the intestinal immune network for IgA production, asthma pathway, and African trypanosomiasis pathway. Here, CD79A is linked to asthma.